Extracellular Matrix Degradation Products Downregulate Neoplastic Esophageal Cell Phenotype

Tissue Eng Part A. 2019 Mar;25(5-6):487-498. doi: 10.1089/ten.TEA.2018.0105.

Abstract

Extracellular matrix (ECM) biomaterials were used to treat esophageal cancer patients after cancer resection and promoted regrowth of normal mucosa without recurrence of cancer. The present study investigates the mechanisms by which these materials were successful to prevent the cancerous phenotype. ECM downregulated neoplastic esophageal cell function (proliferation, metabolism), but normal esophageal epithelial cells were unaffected in vitro, and suggests a molecular basis (downregulation of PI3K-Akt, cell cycle) for the promising clinical results. The therapeutic effect appeared to be enhanced using homologous esophageal ECM. This study suggests that ECM can be further investigated to treat cancer patients after resection or in combination with targeted therapy.

Keywords: cell/matrix interaction; dynamic reciprocity; esophageal cancer; extracellular matrix bioscaffold; gene expression.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Apoptosis
  • Autophagy
  • Cell Cycle
  • Cell Line, Tumor
  • Cell Proliferation
  • Cell Shape
  • DNA Replication
  • Down-Regulation*
  • Esophageal Neoplasms / genetics
  • Esophageal Neoplasms / metabolism
  • Esophageal Neoplasms / pathology*
  • Extracellular Matrix / metabolism*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Phenotype
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphorylation
  • Proto-Oncogene Proteins c-akt / metabolism
  • Signal Transduction
  • Swine
  • Urinary Bladder / metabolism

Substances

  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt